Moses Makunje
Direttore Finanziario/CFO presso NUVATION BIO INC.
Patrimonio netto: 27 803 $ in data 30/04/2024
Profilo
Moses Makunje is currently the Chief Financial & Accounting Officer at Nuvation Bio, Inc. He previously worked as the Corporate Controller at Maze Therapeutics, Inc. from 2019 to 2020.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 29/02/2024 | 10 612 ( 0.00% ) | 27 803 $ | 30/04/2024 |
Posizioni attive di Moses Makunje
| Società | Posizione | Inizio |
|---|---|---|
| NUVATION BIO INC. | Direttore Finanziario/CFO | 27/11/2023 |
Precedenti posizioni note di Moses Makunje
| Società | Posizione | Fine |
|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/07/2020 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NUVATION BIO INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Moses Makunje
